DrugCite
Search

VECTIBIX

Adverse Events
Drug Profile
Learn More
Reference
About Results
Comments

Vectibix Adverse Events Reported to the FDA Over Time

How are Vectibix adverse event reports trending over time?

This graph shows volume of adverse events submitted to the FDA by quarter for Vectibix, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Vectibix is flagged as the suspect drug causing the adverse event.

Most Common Vectibix Adverse Events Reported to the FDA

What are the most common Vectibix adverse events reported to the FDA?

Rash
207 (4.69%)
Dyspnoea
91 (2.06%)
Death
78 (1.77%)
Diarrhoea
78 (1.77%)
Skin Toxicity
69 (1.56%)
Erythema
68 (1.54%)
Hypomagnesaemia
68 (1.54%)
Dermatitis Acneiform
67 (1.52%)
Pyrexia
62 (1.4%)
Skin Reaction
57 (1.29%)
General Physical Health Deteriorati...
47 (1.06%)
Show More Show More
Infusion Related Reaction
47 (1.06%)
Pruritus
46 (1.04%)
Dry Skin
44 (1%)
Malignant Neoplasm Progression
43 (.97%)
Vomiting
42 (.95%)
Folliculitis
41 (.93%)
Hypersensitivity
39 (.88%)
Pain
39 (.88%)
Nausea
38 (.86%)
Rash Pustular
37 (.84%)
Chills
36 (.82%)
Acne
35 (.79%)
Skin Fissures
35 (.79%)
Disease Progression
32 (.72%)
Hypocalcaemia
32 (.72%)
Malaise
32 (.72%)
Paronychia
31 (.7%)
Abdominal Pain
30 (.68%)
Conjunctivitis
30 (.68%)
Mucosal Inflammation
30 (.68%)
Back Pain
29 (.66%)
Stomatitis
29 (.66%)
Paraesthesia
27 (.61%)
Renal Failure
27 (.61%)
Dehydration
24 (.54%)
Decreased Appetite
23 (.52%)
Neutropenia
23 (.52%)
Pulmonary Embolism
23 (.52%)
Fatigue
22 (.5%)
Febrile Bone Marrow Aplasia
22 (.5%)
Infection
21 (.48%)
Dermatitis
19 (.43%)
Hypotension
19 (.43%)
Skin Burning Sensation
19 (.43%)
Skin Exfoliation
19 (.43%)
Thrombocytopenia
19 (.43%)
Urinary Tract Infection
19 (.43%)
Blood Bilirubin Increased
18 (.41%)
Blood Magnesium Decreased
18 (.41%)
Rash Maculo-papular
18 (.41%)
Sepsis
18 (.41%)
Dry Eye
17 (.39%)
Muscle Spasms
17 (.39%)
Swelling Face
17 (.39%)
Tachycardia
17 (.39%)
Anaemia
16 (.36%)
Oedema Peripheral
16 (.36%)
Rash Erythematous
16 (.36%)
Skin Ulcer
16 (.36%)
Asthenia
15 (.34%)
Fall
15 (.34%)
Palmar-plantar Erythrodysaesthesia ...
15 (.34%)
Photosensitivity Reaction
15 (.34%)
Skin Haemorrhage
15 (.34%)
Chest Discomfort
14 (.32%)
Colorectal Cancer
14 (.32%)
Confusional State
14 (.32%)
Febrile Neutropenia
14 (.32%)
Hypertension
14 (.32%)
Interstitial Lung Disease
14 (.32%)
Neoplasm Progression
14 (.32%)
Rash Papular
14 (.32%)
Deep Vein Thrombosis
13 (.29%)
Eye Inflammation
13 (.29%)
Liver Function Test Abnormal
13 (.29%)
Nail Disorder
13 (.29%)
Blood Pressure Increased
12 (.27%)
Eczema
12 (.27%)
Flushing
12 (.27%)
Hyperhidrosis
12 (.27%)
Hypokalaemia
12 (.27%)
Lung Disorder
12 (.27%)
Metastases To Liver
12 (.27%)
Skin Disorder
12 (.27%)
Ascites
11 (.25%)
Blister
11 (.25%)
Bronchospasm
11 (.25%)
Burning Sensation
11 (.25%)
Cough
11 (.25%)
Hypophagia
11 (.25%)
Loss Of Consciousness
11 (.25%)
Metastases To Lung
11 (.25%)
Oral Pain
11 (.25%)
Pain In Extremity
11 (.25%)
Pneumonia
11 (.25%)
Respiratory Failure
11 (.25%)
Weight Decreased
11 (.25%)
Abdominal Pain Upper
10 (.23%)
Blood Creatinine Increased
10 (.23%)
Cyanosis
10 (.23%)

ExportShare/Embed GraphExport Export Data

This graph shows the top adverse events submitted to the FDA for Vectibix, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Vectibix is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Adverse Event Categories for Vectibix

What are the most common Vectibix adverse events reported to the FDA?

Show More Show More

ExportShare/Embed Graph Export Export Data

This graph shows the top categories of adverse events submitted to the FDA for Vectibix, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Vectibix is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Common Uses of Vectibix According to Those Reporting Adverse Events

Why are people taking Vectibix, according to those reporting adverse events to the FDA?

Colorectal Cancer
711
Drug Use For Unknown Indication
151
Product Used For Unknown Indication
101
Colorectal Cancer Metastatic
82
Colon Cancer
65
Gastrooesophageal Cancer
40
Show More Show More
Colon Cancer Metastatic
31
Breast Cancer
29
Rectal Cancer Metastatic
11
Pre-existing Disease
6
Oesophageal Carcinoma
6
Neoplasm Malignant
6
Bile Duct Cancer
5
Rectal Cancer
4
Metastases To Liver
4
Large Intestine Carcinoma
4
Ovarian Cancer
4
Non-small Cell Lung Cancer
3
Transitional Cell Carcinoma
3
Colorectal Cancer Stage Iv
3
Prostate Cancer
2
Metastases To Lung
2
Renal Cell Carcinoma Stage Unspecif...
2
Colon Neoplasm
1
Hepatic Neoplasm Malignant
1
Pancreatic Carcinoma
1
Small Intestine Carcinoma
1
Squamous Cell Carcinoma
1
Gastric Cancer
1
Nasopharyngeal Cancer
1
Head And Neck Cancer
1
Rectal Neoplasm
1
Adenocarcinoma
1
Chemotherapy
1

Drug Labels

LabelLabelerEffective
VectibixAmgen Inc28-MAR-13

Vectibix Case Reports

What Vectibix safety concerns are being reported by doctors and researchers in the medical literature?

Powered by Google

About Results

This report contains aggregated drug side effects and adverse events for Vectibix. The data has been pulled from the United States Food and Drug Administration's (US FDA) Adverse Event Reporting System (AERS), a database containing more than 4,000,000 adverse event reports.

DrugCite expands your query using the Unified Medical Language System (UMLS) to include generic drugs and primary active ingredients. While the core of DrugCite's advanced drug filtering algorithm is based on the industry standard UMLS, DrugCite's proprietary filtering system also includes dozens of additional steps to reconcile malformed drug names in the FDA's data.

DrugCite only counts a drug if the submitter of the adverse event indicates that the drug is suspected to have caused the adverse event.

Depending on how the data is aggregated, different counts may occur. When someone submits an adverse event to the FDA, the submitter can attribute multiple adverse events to one or more drugs. For example, an individual taking Paxil could submit the adverse events "anxiety" and "suicidal ideation" for the same individual safety report (ISR). This means when DrugCite aggregates by adverse event, two distinct adverse events are counted in the adverse event graph; once for "anxiety" and again for "suicidal ideation". However, when DrugCite aggregates by individual safety reports irrespective of the details of the adverse events contained within the safety report, the report is only counted once.

Comments

Share your experience with Vectibix.